Browse by People


Up a level
Export as [feed] RSS [feed] RSS 2.0 Short Author List
Number of items: 4.


Au, Lewis, Hatipoglu, Emine, Robert de Massy, Marc, Litchfield, Kevin, Beattie, Gordon, Rowan, Andrew, Schnidrig, Desiree, Thompson, Rachael, Byrne, Fiona, Horswell, Stuart
et al (show 195 more authors) (2021) Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. Cancer Cell, 39 (11). 1497-1518.e11.


Middleton, Gary, Greenhalf, William, Costello, Eithne, Shaw, Victoria ORCID: 0000-0002-0429-0186, Cox, Trevor, Ghaneh, Paula, Palmer, Daniel H ORCID: 0000-0002-7147-5703 and Neoptolemos, John P
(2016) Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma. British Journal of Cancer, 114 (5). pp. 510-518.


Middleton, Gary, Brock, Kristian, Savage, Joshua, Mant, Rhys, Summers, Yvonne, Connibear, John, Shah, Riyaz, Ottensmeier, Christian ORCID: 0000-0003-3619-1657, Shaw, Paul, Lee, Siow-Ming
et al (show 4 more authors) (2020) Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial. The Lancet Respiratory Medicine, 8 (9). pp. 895-904.


Middleton, Gary, Palmer, Daniel H ORCID: 0000-0002-7147-5703, Greenhalf, William, Ghaneh, Paula, Jackson, Richard, Cox, Trevor, Evans, Anthony ORCID: 0000-0001-8547-1730, Shaw, Victoria E ORCID: 0000-0002-0429-0186, Wadsley, Jonathan, Valle, Juan W
et al (show 14 more authors) (2017) Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial. The Lancet Oncology, 18 (4). pp. 486-499.

This list was generated on Tue Feb 6 05:24:54 2024 GMT.